Loading patent…
AssigneeThe Brigham and Women's Hospital, Inc. Corporate Sponsored Research and Licensing
InventorsCharles N. Serhan, Rong Yang
Estimating the term…
The invention relates to the use of microfluidic chemotaxis device to identify novel active compounds of the metabolome and methods to characterize their actions on cell motility. The invention also includes the active compounds of the metabolome identified by the methods and devices disclosed herein. The results from these in vitro experiments were then correlated with in vivo physiologic responses to identify the downstream effects and therapeutic value. Thus, the invention provides novel methods for treating or preventing second organ injury resulting from ischemia-reperfusion in a patient in need thereof The invention also provides methods of treating, preventing or ameliorating connective tissue degeneration in a patient in need thereof. The invention also provides methods of treating or preventing bone loss. In addition, the invention provides method for inducing bone regeneration in patients in need thereof or preventing bone loss in patients suspected to be in need thereof.
A method for treating or preventing second organ injury resulting from ischemia-reperfusion comprising administering to a patient suffering or at risk of suffering second organ injury resulting from ischaemia-reperfusion comprising a therapeutically effective amount of a resolvin or protectin selected from compounds I through LXXXIV.
A method of treating, preventing or ameliorating connective tissue degeneration in a patient in need thereof, comprising administering a therapeutic amount of a resolvin or protectin selected from compounds I through LXXXIV.
A method of treating or preventing bone loss comprising administering a therapeutically effective amount of a resolvin or protectin selected from compounds I through LXXXIV.
Dependencies are inferred from the claim text.